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Studies of lentivirus infection in ruminants, nonhuman primates, and humans suggest that virus infection of 
macrophages plays a central role in the disease process. To investigate whether human immunodeficiency virus 
type 1 (HIV-1) can infect chimpanzee macrophages, we recovered monocytes from peripheral blood 
mononuclear cells of HIV-1-negative animals and inoculated these and control human monocytes with a panel 
of four human-passaged monocytotropic virus strains and one chimpanzee-passaged isolate. HIV-1-infected 
human monocytes synthesized proviral DNA, viral mRNA, p24 antigen, and progeny virions. In contrast, 
except for the chimpanzee-passaged HIV-1 isolate, chimpanzee monocytes failed to support HIV-1 replication 
when cultured under both identical and a variety of other conditions. Proviral DNA was demonstrated only at 
background levels in these cell cultures by polymerase chain reaction for gag- and env-related sequences. 
Interestingly, the chimpanzee-passaged HIV-1 isolate did not replicate in human monocytes; viral p24 antigens 
and progeny virions were not detected. The same monocytotropic panel of HIV-1 strains replicated in both 
human and chimpanzee CD4+ T lymphoblasts treated with phytohemagglutinin and interleukind. The failure 
of HIV-1 to infect chimpanzee monocytes, which can be overcome by serial in vivo viral passage, occurs 
through a block early in the viral life cycle. 
Chimpanzees and gibbon apes are the only primates other phages plays a major role in the disease process (6, 11, 17, 
than humans susceptible to human immunodeficiency virus 18-20,22-24, 31,35). However, in HIV-1-infected chimpan- 
type 1 (HIV-1) infection (2, 7, 12, 14-16, 25). Chimpanzees zees, the identification of monocytes/macrophages as host 
are readily infected with as little as four tissue culture cells for virus is lacking. Previously, we demonstrated that 
infectious doses (TCID) of virus (3). Following virus inocu- CD4+ T cells from peripheral blood mononuclear cells 
lation, similarities between viral replication and the immune (pBMCs) of uninfected donor chimpanzees readily support 
response to viral infection in chimpanzees and humans low levels of virus replication, induce minimal fusion, and 
abound. Virus isolation precedes seroconversion to both serve as targets for laboratory strains of virus passaged in 
and ~ 2 4  antigen (Ag)-positive status within 4 to 6 human T-cell lines in the infected host (28). However, 
weeks of virus challenge (3, 14-28]. Persistent replication is monocytes recovered from HIV-1 IIIB-infected chimpan- 
evidenced by sequential virus reisolations over periods of zees given human T-cell-passaged isolates were virus nega- 
months to years (3, 14) and the emergence of neutralization tive both by cocu~tivation with human phytohemagglutinin- 
escape mutants (30). Despite these observations, all clinical and-interleukin-2 (PHmL-2)-stimulated lymphoblasts and by 
and laboratory parameters, including total numbers of CD4+ polymerase chain reaction (PCR) for viral DNA (27, 28). T cells, for all but 1 of more than 100 animals inoculated plasma viremia, central nervous system disease, and 
worldwide thus far remained within the normal range. How- lymphatic hyperplasia all characterize human HIV-1 infec- 
ever, one research group observed a single animal which tion but are absent in HIV-1-infected chimpanzees (27, 28). developed transiently depressed CD4+ T cells and platelet Both central nervous system and lymph node diseases in 
numbers following inoculation with several strains of HIV-1 humans are characterized by a productive and persistent (13). Proliferative and variable cytotoxic T-cell responses to infection of resident macrophages and dendritic cells. Al- HIV-l-specific Ags (7, 37) as well as neutralizing antibody though chimpanzees may develop generalized lymphadenop- 
activities (I4, 29, 30) have been in athy, their lymph nodes show only plasmacytosis, perhaps 
infected chimpanzees. Each of these host responses is also 
secondary to the intravenous administration of large inocula found in infected humans. 
Studies of lentivirus infection of ruminants, nonhuman of virus preparations containing many foreign human cellular 
primates, and humans suggest that virus infection of macro- The mechanisms surrounding the differences between 
HIV-1 infection of humans and chimpanzees are of potential 
* Corresponding author. importance in understanding disease pathogenesis, in devel- 
1. Present address: Molecular Diagnostic Unit, Department of oping effective vaccines, and in developing therapeutic in- 
Pathology, University of Pittsburgh, Pittsburgh, PA 15261. terventions. For example, virus-macrophage interactions for 
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binding, penetration, uncoating, or replication in chimpan- 
zee and human cells may differ. To these ends, we studied 
the ability of HIV-1 to replicate in its two major target cells 
in chimpanzees, monocytes and CD4+ T lymphocytes. To 
date, HIV-1 variants that preferentially replicate in human 
monocytes have not yet been inoculated in chimpanzees, nor 
has there been a formal in vivo demonstration that macro- 
phages from any organ-specific compartment contain virus. 
Perhaps, the ability of particular viral strains to productively 
infect monocyteslmacrophages is a necessary event for 
disease in the chimpanzee. 
MATERIALS AND METHODS 
Isolation and culture of human and chimpanzee monocytes 
and T lymphoblast target cells. Human monocytes were 
recovered from PBMCs of HIV-1- and hepatitis B-seroneg- 
ative donors after leukapheresis and purified by adherence 
or by countercurrent centrifugal elutriation of mononuclear 
leukocyte-rich fractions of blood cells as previously de- 
scribed (18, 23). Chimpanzee monocytes recovered from 
PBMCs of eight HIV-1-seronegative animals were purified 
by adherence onto plastic tissue culture dishes. For select 
experiments, Ficoll-Hypaque-purified PBMCs were infected 
directly with HIV-1 and subsequently purified into either the 
T-cell or monocyte fraction by culture techniques outlined 
below. Combined adherence and antibody- and complement- 
mediated depletion of T lymphocytes were performed with 
OKT3 and rabbit complement. As previous studies describ- 
ing the isolation and culture of human monocytes demon- 
strated that supplementation of the medium with specific 
cytokines improved long-term culture (6, 23), optimal cul- 
ture conditions for chimpanzee monocytes were determined. 
Monocytes from both species at variable cell concentrations 
(0.1 x lo6 to 1.0 x lo6 cells per 24-mm-diameter tissue 
culture well) were cultured with or without exogenous cell 
growth factors. These included: heat-inactivated A' human 
serum, autologous chimpanzee serum, granulocytelmacro- 
phage colony-stimulating factor (GMCSF) (Genzyme, Bos- 
ton, Mass.), recombinant human macrophage CSF (MCSF) 
(a generous gift from Cetus Corp., Emeryville, Calif.), and 
conditioned medium from PHAIIL-2-treated chimpanzee 
PBMCs. Media tested included Dulbecco modified Eagle 
medium (formula 78-176AJ; GIBCO, Grand Island, N.Y.), 
RPMI 1640 (GIBCO), and AIM V (GIBCO). Macrophages 
were removed after 1 week of culture by gentle scraping with 
a rubber policeman in cold phosphate-buffered saline defi- 
cient in magnesium and calcium. Total viable cells were 
counted by the trypan blue dye exclusion assay. Functional 
analysis of the specific cell type was determined by their 
ability to phagocytize latex and carboxylate beads. Human 
and chimpanzee PBMCs, isolated from whole blood by 
Ficoll-diatrizoate density gradient centrifugation, were cul- 
tured at lo6 viable cells per ml in RPMI 1640 medium 
(GIBCO) with 5 pg of PHA (Sigma Chemical Co., St. Louis, 
Mo.) per ml, 10% purified human IL-2 (Advanced Biotech- 
nologies Inc., Columbia, Md.), and 15% heat-inactivated 
fetal calf serum (Sterile Systems, Inc., Logan, Utah). 
Animals. Housing conditions for the chimpanzees and the 
serological assays used to detect HIV-1 antibodies were 
previously described (3,4). All animals used as blood donors 
for the virus assays were HIV-1 seronegative. The animals 
were examined by staff veterinarians every 2 weeks. 
HIV-1 infection of monocyte and T-cell targets. PHAlIL-2- 
treated lymphoblasts and monocytes were exposed to HIV-1 
at a multiplicity of infection (MOI) of 0.01 infectious virus 
per target cell. Four HIV-1 strains originally isolated and 
passaged in human primary monocytes (strains ADA, 36, 
105, and 24) (18, 23), one strain passaged in T-cell lines 
(HIV-1 IIIB), and one chimpanzee serial-passaged isolate 
(HIV-lLAVlb) (14, 36) were employed. The TCID was deter- 
mined by serial dilution of stock virus onto target human 
monocytes or lymphoblasts. HIV-1 IIIBlH9 (R. Gallo, con- 
tributor) was obtained from the AIDS Research and Refer- 
ence Reagent Program, AIDS Program, National Institute of 
Allergy and Infectious Diseases, and the virus titer on 
human and chimpanzee lymphoblasts was determined to be 
lo4 50% TCID (TCID,,). HIV-1 IIIB was passaged through 
transformed chimpanzee CD4+ cell lines and designated 
HIV-1 IIIBICHM-114 (28). PHAIIL-2-treated lymphoblasts 
previously cultured for 3 days were infected in medium 
supplemented with either 2 pg of Polybrene (Sigma Chemi- 
cal Co.) or 25 pg of diethylaminoethyl-dextran (Pharmacia, 
Piscataway, N.J.) per ml. Monocytes were infected in bulk 
PBMCs or cultured as adherent monolayers for 0 to 10 days 
prior to use as target cells. Monocytes or PBMCs were 
washed twice in complete medium after a 1-h incubation at 
37°C with virus. All cultures were refed with fresh medium 
every 2 to 3 days at which time culture fluids, cells, andlor 
DNA were removed or isolated for viral quantitation and 
electron microscopy. Lymphocyte and monocyte cultures 
were maintained for 14 to 21 days and 20 to 30 days, 
respectively, following infection. Levels of p24 Ag in culture 
fluids were determined by enzyme-linked immunosorbent 
assays (E. I. Dupont de Nemours & Co., Billerica, Mass.). 
For reverse transcriptase (RT) activity, replicate samples of 
culture fluids were added to a reaction mixture of Nonidet 
P-40 (Sigma), poly(rA). oligo(dT) (Pharmacia), dithiothreitol 
(Pharmacia), MgCI,, and [a-"PIdTTP (400 Cilmmol; Amer- 
sham Corp., Arlington Heights, Ill.) for 24 h at 37°C. The 
mixture was applied to chromatography paper, air dried, and 
washed five times in 0.3 M NaCI-0.03 M sodium citrate (pH 
7.4) and twice more in 95% ethanol. The paper was dried and 
cut, and the radioactivity was counted by liquid scintillation 
spectroscopy. HIV-1 IIIB served as the positive control for 
both p24 Ag and RT activity assays. 
Detection of HIV-1-specific DNA by PCR amplification. All 
PCR amplification specimens were coded, and assays were 
performed in a blind manner. Cellular lysates of HIV-1- 
infected cells were extracted once each with phenol and then 
chloroform-isoamyl alcohol (24:l) prior to ethanol precipita- 
tion. PCR amplification of HIV-1 proviral DNA was per- 
formed using gag- (SK38139) and env-(SK68169)-specific 
primer pairs (1, 9). PCR was performed for 30 cycles, using 
an automatic thermal cycler (Perkin-Elmer Cetus, Norwalk, 
Conn.) and Taq polymerase (Perkin-Elmer Cetus) as previ- 
ously described (10). All amplifications used 1 pg of chro- 
mosomal DNA as an initial target, and each run was accom- 
panied by a positive-control dilution series and known 
negative and reagent controls. In all cases, <20 copies of 
HIV-1 proviral DNA were detected. Assessment of specific 
amplification was determined by liquid hybridization of the 
PCR products with "P-end-labeled oligonucleotide detector 
probes SK19 gag and SK70 env (1, 9), followed by gel 
electrophoresis (10). 
In situ hybridization with HIV-1 RNA probes. Single- 
stranded HIV-1 ["SIRNA probes were synthesized from a 
recombinant DNA plasmid containing SP6lT7 promoters 
(Promega Biotec, Madison, Wis.) (21). Cytosmears or adher- 
ent cells grown on glass slides treated with silane were fixed 
in 4% paraformaldehyde. Specimens were prehybridized in a 
solution consisting of 10 mM Tris (pH 7.4), 0.3 M NaCI-0.03 
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M sodium citrate (pH 7.4), Denhardt solution [0.02% poly- 
-- 
vinylpyrrolidone, 0.02% Ficoll, 0.02% bovine serum albu- -rc 
min), and 200 pg of yeast tRNA per ml at 45°C for 2 h and 
hybridized in this solution with 10% dextran sulfate, 5 pM 
dithiothreitol, and 35S-labeled HIV-1 RNA (lo6 cpm; Oncor, a 
Inc., Gaithersburg, Md.). Slides were serially washed in J 3 -, ,.j 
solutions with RNase to reduce binding of nonhybridized a 
rCD probe. Autoradiography was performed in absolute darkness 1 /*' n 2 
(21). -4 
~ransmission electron microscopy. Monocytes or lympho- 
blast cultures in microtiter plates were fixed in 2% glutaral- " 
dehyde in cacodylate buffer and treated with osmium tetrox- 
ide (23). The fixed cells were dehydrated, embedded in 
Epon, and mounted for sectioning parallel to the culture 
surface. Blocks were first thick sectioned and stained with 
toluidine blue for light microscopic observations. Those 
areas of interest were further thin sectioned, stained with 
uranyl acetate, and examined with a Zeiss electron micro- 
scope. Approximately 1,000 chimpanzee monocytes from 
three different experiments were evaluated for evidence of 
cell surface or vacuolar budding of HIV-1 particles. 
RESULTS 
Maintenance and cultivation of human and chimpanzee 
monocytes. Previous studies demonstrated that cell differen- 
tiation affects the susceptibility of monocytes to lentiviral 
infection (22). In this regard, an evaluation of numerous 
culture conditions that could affect monocyte/macrophage 
differentiation was performed. Optimal cell viabilities were 
obtained at cell concentrations of 7.5 x lo5 cells per ml in 
each well of a 24-mm-diameter tissue culture plate. Signifi- 
cant differences between cells cultured in Dulbecco modified 
Eagle medium and RPMI 1640 were not demonstrated (data 
not shown). In numerous assays, monocytes from humans 
and chimpanzees cultured without cytokines and with 
MCSF, GMCSF, or combinations of MCSF and GMCSF 
yielded 20, 70,70, and 85%, respectively, viable cells after 1 
week in culture. Cells maintained in the absence of CSFs 
were flattened and pyknotic. Human and chimpanzee mono- 
cytes cultured in AIM V demonstrated -75 and 95% cell 
viability after 1 week with or without the addition of CSFs. 
Morphologically, chimpanzee monocyte cultures demon- 
strated a heterogeneous appearance, with fusiform cells, 
cells with fibroblastlike features, and rounded cells with 
diffuse cytoplasm (Fig. 1A and B). Ultrastructurally, mono- 
cytes had highly irregular cell surfaces with numerous mi- 
crovillar lamellipodia and subplasmalemma densities. The 
cytoplasm contained numerous mitochondria, bundles of 
microfilaments, moderate amounts of rough endoplasmic 
reticulum, free ribosomes, and multiple well-developed 
Golgi complexes. In addition, numerous phagocytic vacu- 
oles, granules with electron-dense homogeneous contents 
(azurophil granules), secondary lysosomes, residual bodies, 
FIG. 1. Morphology of cultured chimpanzee monocytes. Chim- 
panzee PBMCs were purified to >94% monocytes and cultured for 
7 days as adherent monolayers in medium with human serum and 
GMCSF. All cultures were refed with fresh medium every 2 to 3 
days. Studies of the morphology of cultured monocytes demon- 
strates a heterogeneous monocyte population, with fusiform cells, 
cells with fibroblastlike features, and rounded cells with diffuse 
cytoplasm. Low-power ( ~ 2 5 0 ;  Hoffman modulation) (A) and high- 
power ( ~ 4 5 0 ;  Hoffman modulation) (B) magnifications. Nonspecific 
esterase reactivity at day 14 of culture (C) is illustrated. 
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FIG. 3. HIV-1 proviral DNA in human and chimpanzee mono- 
cytes following virus inoculations. PBMCs purified to >94% and 
98% monocytes for chimpanzee and human cells, respectively, were 
cultured for 7 days as adherent monolayers in medium with human 
serum and infected with isolates ADA (A) or 36 (B) at a MOI of 0.01. 
Autoradiographs show samples from HIV-1-infected monocytes 
from chimpanzee and human PBMCs cultured for 8 h or 7 or 14 
days. (A) Samples from HIV-1 ADA-infected chimpanzee and 
human monocytes. Lane 1, Chimpanzee cells with no virus cultured 
for 14 days; lanes 5 and 6, 8 h and 14 days, respectively, following 
HIV-1 inoculation of chimpanzee monocytes; lanes 2, 3, and 4, 14 
days, 7 days, and 8 h, respectively, following HIV-1 inoculation of 
human monocytes. The lambda DNA negative (lanes 7 to 9) and 
proviral DNA positive controls (lanes 10 to 12) are illustrated. (B) 
Samples from HIV-1 36-infected chimpanzee and human mono- 
cytes. Lanes 1 and 2, 8 h and 7 days, respectively, following virus 
inoculation of chimpanzee monocytes; lanes 3 and 4,7 and 14 days, 
respectively, following virus inoculation of human monocytes; lane 
5, uninfected human monocytes; lane 6, ADA-infected human 
PBMCs; lane 7, HIV proviral DNA positive control. 
Days After Infection 
FIG. 2. Infection of HIV-1 ADA monocytotropic stock virus 
onto human and chimpanzee monocytes. PBMCs purified to >98% 
monocytes and cultured for 7 days as adherent monolayers in 
medium with human serum and MCSF were exposed in duplicate 
determinations to HIV-1 isolate ADA. (A) Human monocytes 
infected with 10-fold dilutions of viral inoculum (0 ,  undiluted; +, 
1:lO; 0, 1:100; 0, 1:1,000; @, 1:10,000; W, 1:100,000). (B) Viral 
replication following the inoculation of human (0) and chimpanzee 
(W) monocytes with HIV-1 ADA at a MOI of 0.01. All cultures were 
refed with fresh medium every 2 to 3 days, and the culture fluids 
were saved at the indicated times and later assayed for p24 Ag and 
RT activity. 
and lipid inclusions were seen (see Fig. 4). The isolated cells 
were nonspecific esterase and granular peroxidase positive 
(Fig. 1C). Phagocytosis of latex particles was further dem- 
onstrated in the cultured cells after 1 week (data not shown). 
Chimpanzee monocytes adhering to plastic were 92 to 98% 
pure after 1 week in culture with or  without complement and 
antibody lysis of contaminating T cells. Residual lymphocytes 
could be found associated with monocytes for periods of >2 
weeks in the absence of exogenous PHA or IL-2 (see Fig. 4). 
Minimal levels (52% contaminating cells) were achieved by 
complement- and antibody-mediated lysis of the contaminating 
cell populations. 
Infection of human and chimpanzee monocytes with HIV-1. 
The ability of chimpanzee monocytes to support HIV-1 
replication was analyzed. Two virus strains with demon- 
strated tropism for human monocytes (ADA and 36) (18,23) 
and one chimpanzee-passaged HIV-1 isolate were used in 
initial studies in attempts to infect chimpanzee monocytes. 
The titers of the viral stocks in human monocytes were lo5, 
lo4, and 0 TCID,, for strains ADA, 36, and HIV-lLAvIb9 
respectively. A representative titration of HIV-1 ADA (10- 
fold serial dilutions of virus stock inoculated onto 7-day-old 
human monocytes) is illustrated in Fig. 2A. Following infec- 
tion of human monocytes with ADA (MOI = 0.1), p24 Ag 
levels were initially detected in culture fluids at 3 to 5 days, 
with maximum levels of 250 nglml and RT levels in excess 
of 60 x lo6 cpmlml. Typical cytopathic effects, including 
multinucleated giant cell formation and cell lysis, are seen 
beginning by day 7 following infection in the human cells. 
Chimpanzee monocytes from four different donors were 
inoculated with the three virus strains at an MOI of 0.1 or 
0.01. The cells were cultured in media supplemented with 
MCSF (1,000 Ulml), GMCSF (100 Ulml), or  MCSF and 
GMCSF (1,000 and 100 Ulml, respectively). Monocytes 
were inoculated with virus after 7 days of culture. A repre- 
sentative experiment is shown in Fig. 2B. Productive viral 
replication could not be demonstrated for either ADA or 36 
in any of the four chimpanzee monocyte populations. p24 Ag 
and RT activity assays performed on culture supernatants 
produced negative results, and there was no evidence of 
syncytium formation or  cell death upon microscopic evalu- 
ation. The lack of productive virus replication in chimpanzee 
monocytes with human-passaged monocytotropic HIV-1 
strains was evident regardless of culture conditions (includ- 
ing infection of monocytes directly in the bulk PBMCs), 
timing of infection, or the age or sex of the animal donor 
(data not shown). 
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FIG. 4. Electron microscopic observations of HIV-1-inoculated chimpanzee monocytes. Chimpanzee PBMCs purified to >94% mono- 
cytes were cultured 7 days as adherent monolayers in medium with chimpanzee serum and GMCSF and infected with isolate ADA at a MOI 
of 0.01 for up to 21 days. Progeny virions were not demonstrated, but contaminating T cells are shown phagocytized by these monocytes. 
(A) A 5-day-old culture of a typical macrophage with a irregular lamellipodia surface and eccentric nucleus; adjacent small lymphocytes are 
seen. Magnification, ~13,200.  (B) A monocyte-associated lymphocyte in a 14-day-old culture. Note the apparent normal ultrastructural 
appearance of the lymphocyte. Magnification, ~12,000. (C) A lymphocyte within a cytoplasmic vacuole of a monocyte. 
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FIG. 5. HIV-1-specific mRNA in virus-inoculated human and chimpanzee cells. Human and chimpanzee PBMCs purified to 94 and 98% 
monocytes, respectively, were cultured for 7 days as adherent monolayers in medium with chimpanzee or human serum and MCSF. Cells 
were infected with isolate ADA at a MOI of 0.01 for 14 days. Human PHAIIL-2-stimulated lymphoblasts infected with ADA for 7 days at a 
MOI of 0.01 served as a positive control for this assay. Autoradiography revealed silver grains over HIV-1 mRNA-producing cells. 
HIV-1-infected human macrophages (A) and human PBMCs (B) demonstrate abundant HIV-1 mRNA-containing cells following virus 
inoculations. Chimpanzee macrophages cultured and infected as the human cells show no measurable HIV-1 mRNA (C). 
To analyze the stage of the virus life cycle restricted by the 
chimpanzee monocyte, we performed a systematic analysis 
of HIV-1 replication following virus infection. PCR amplifi- 
cation for HIV proviral DNA in control HIV-1-infected 
human monocytes (ADA or  36) showed high levels of 
amplified products at 7 and 14 days. However, amplification 
of DNA extracted from HIV-1-infected chimpanzee mono- 
cytes at  these time intervals produced barely detectable 
signals ( 4 %  of human control monocytes) following liquid 
hybridization analyses (Fig. 3). The low levels of proviral 
DNA seen in HIV-1-inoculated chimpanzee monocyte cul- 
tures were typical of that demonstrated in other viral stock 
preparations (8). In an attempt to resolve whether the low 
levels of HIV-1 DNA were due to input DNA or contami- 
nating lymphocytes in the monocyte preparations, we 
treated monocyte cultures with OKT3 and complement prior 
to virus infection. Although a reduced PCR signal was 
demonstrated, amplification products could still be visual- 
ized (data not shown). This suggested that the viral inocula 
was a source of the contaminating HIV DNA. Indeed, 
analysis by electron microscopy of chimpanzee monocyte 
cultures not treated with OKT3 and complement showed 
rare but viable T cells in the cell preparations (Fig. 4). No 
budding viral particles were ever seen by electron micros- 
copy in these contaminating lymphocytes. This explanation 
is further supported by the absence of viral RNA and 
progeny virion production in HIV-1-inoculated chimpanzee 
monocyte cultures. Of the cells infected with human-pas- 
saged HIV-1, 10 and 70% after 7 and 14 days, respectively, 
were demonstrated by in situ hybridization to be expressing 
HIV-1-specific mRNAs (Fig. 5A). In contrast, no viral 
RNAs could be detected in either ADA- or 36-infected 
chimpanzee monocytes (Fig. 5C). Production of progeny 
HIV-1 particles was evaluated at 7, 14, and 21 days by 
transmission electron microscopy. In human cultures, viri- 
ons were easily identified in intracytoplasmic vacuoles and 
via budding from the plasma membrane (Fig. 6). However, a 
survey of over 1,000 chimpanzee monocytes in independent 
laboratories failed to identify vacuolar or  membrane-associ- 
ated virus particles at any point following infection. These 
results were obtained regardless of whether the chimpanzee 
monocytes were prepared for culture immediately following 
phlebotomy or 18 h later. Thus, by analyses of proviral 
DNA, viral mRNA, p24 viral Ag, RT activity, and ultrastruc- 
tural virion production, HIV-1 infection was not demon- 
strated in chimpanzee monocytes with these human-pas- 
saged monocytotropic virus strains. 
HIV-1 replication in human and chimpanzee PBMCs and 
monocytes: a comparison with a panel of viral isolates. To 
substantiate the lack of HIV-1 replication with human- 
passaged virus in chimpanzee monocytes, virus growth in 
lymphoblasts and monocytes from identical donor cells was 
examined. Virus from a panel of four monocytotropic strains 
and one lvmvhotrovic HIV-1 strain (HIV-1 IIIB) (Table 1) 
were inochated at ibentical MOIs onto human and chimpan: 
zee monocytes or lymphoblasts. Virus titer, viral mRNA 
levels, and maximum levels of released p24 Ag were deter- 
mined in the virus-inoculated cells. Both human and chim- 
panzee lymphoblasts supported productive virus replication 
when infected with the human- or chimpanzee-passaged 
monocytotropic or lymphotropic strain (Table 1). Titers of 
each of the virus stock preparations were similar for the 
PBMCs of both species and ranged from 10' TCID,, for 
isolate 105 to lo4 for ADA. In each instance, the maximum 
level of p24 Ag released into culture fluids of infected 
lymphoblasts was greater in human cells (60 to 80 ng) than in 
chimpanzees (4 and 3 ng) for ADA and HIV-1 IIIB, respec- 
tively. The level of p24 Ag correlated with the numbers of 
progeny virions observed by electron microscopy (Fig. 7). 
Human lymphoblasts underwent ultrastructural degenera- 
tion and cytolytic changes following human-passaged HIV-1 
infection, and approximately 1 in 10 cells examined demon- 
strated budding or cell-associated virus particles. Progeny 
virions associated with or budding from human-passaged 
HIV-1-infected chimpanzee lymphoblasts made up approxi- 
mately 1 in 100 of total cells examined. No degenerative 
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FIG. 6. Electron microscopic observations of HIV-1-infected human monocytes. Human PBMCs were purified to >94 to >98% 
monocytes, cultured for 7 days in medium supplemented with MCSF, and infected with ADA at a M01 of 0.01 for 14 days. (A) HIV-1 ADA- 
infected human monocytes; (B) same monocytes magnified to show extracellular and intravacuolar particles. 
3860 GENDELMAN ET AL. J .  VIROL. 
TABLE 1. Viral titers" and levels of p24 Agb in culture fluids of monocytes and lymphoblasts infected with five HIV-1 isolates 
Human PBMCs Chimpanzee PBMCs Human monocytes Chimpanzee monocytes 
Virus isolate 
Titer ~ 2 4  Ag Titer ~ 2 4  Ag Titer ~ 2 4  Ag Titer ~ 2 4  Ag
ADA lo-4 80 lo-' 5 95 0 0 
36 lo-3 55 N D" N D  lo-4 65 0 0 
24 lo-3 50 1 60 0 0 
105 lo-z 12 0.4 N D  8 N D  N D  
HIV-1 IIIB 10-4 60 3 o o ND ND 
H I V - ~ L A V ~ ,  ND ND 10-3 30 o o 10-3 9 
" Titer represents the last dilution positive for viral replication as determine 
The p24 Ag levels (in nanograms per milliliter) were measured as describe 
ND, Not done. 
changes were seen at an ultrastructural level in chimpanzee 
lymphocytes budding human-passaged HIV-1 progeny viri- 
ons (Fig. 7A and B). Infection with the chimpanzee-passaged 
HIV-l,,,,, isolate, however, resulted in high levels of 
viral replication (Table 1). All four human-passaged mono- 
cytotropic HIV-1 strains replicated in human monocytes. 
The TCID5,s (lo2 to lo5) of these viral strains were similar 
in human and chimpanzee PBMCs (Table 1). Productive 
viral replication was not demonstrated in chimpanzee mono- 
cytes with any of the human-passaged viral strains tested. 
However, and in contrast to these previous observations, 
HIV-lLAv-lb, the only viral isolate passaged in chimpanzees, 
produced easily detectable levels of p24 Ag and progeny 
virions in virus-inoculated primary chimpanzee monocytes. 
Moreover, virus-induced cytopathicity, multinucleated giant 
cells, and cell death were demonstrated in both virus- 
infected lymphoblasts and monocytes. In lymphoblasts, 
significantly higher levels of p24 Ags, compared with those 
of the human-propagated strains, were seen in culture fluids 
of infected cells. These results taken together clearly dem- 
onstrate that serial in vivo virus passage in chimpanzees 
results in phenotypic changes of the virus strain. The ability 
of this host cell adaptation to produce clinical disease in 
chimpanzees awaits further analyses. 
DISCUSSION 
Chimpanzees and gibbon apes are the only experimental 
animal species shown to be infectable with HIV-1(24,7,12,  
14-16, 25, 28-30). As the chimpanzee is the closest living 
relative of Homo sapiens, the shared permissiveness for 
HIV-1 is consistent with a genus- or species-specific rela- 
tionship usually exhibited by animal lentiviruses. Indeed 
intravenous, vaginal, or intracerebral experimental inocula- 
tion with either culture supernatants of HIV-1-infected cells 
or plasma, brain, or thymic suspensions of AIDS patients 
results in a persistent cell-associated viremia in infected 
chimpanzees (3,  7, 14, 28, 29). Despite the continuous 
reisolation of virus for years, the CD4+ T-cell tropism, and 
the development of an HIV-1-specific antibody response, 
none of the more than 100 virus-inoculated animals reported 
show clinical, hematological, or pathological signs of dis- 
ease. Except for a single report (14), the absence of plasma 
viremia following experimental inoculation with HIV-1 or 
virus-containing clinical tissues remains a unique feature of 
chimpanzee infections. These observations are in sharp 
contrast to the clinical and pathological sequelae observed in 
humans and demonstrate important differences between the 
interactions of HIV-1 in humans and chimpanzees. These 
clinical and pathological differences may correlate with 
resistance to HIV-1 infection of chimpanzee monocytes in 
d by p24 Ag capture assay. 
d in Materials and Methods. 
vivo or with limited involvement of the reticuloendothelial 
cell system. 
This examination of the human-passaged HIV-1-infected 
chimpanzee monocyte demonstrates restriction of infection 
at an early stage in the virus life cycle. However, these 
analyses do not preclude the possibility of in vivo infection, 
as isolated monocytes from blood behave biologically and 
functionally differently than tissue macrophages. However, 
as multiple culture conditions were utilized in attempts to 
optimize in vitro infection without success, it appears that in 
vitro susceptibilities between chimpanzee and human mono- 
cytes for HIV-1 of human passage are distinct. Only low 
levels of proviral DNA were detected in the absence of 
virus-specific mRNA. This suggests that the block may be 
mediated early, at the level of receptor-virus interaction(s) 
or cell-to-cell transmission. Indeed, the CD4 molecule, the 
receptor for HIV-1 in virus-susceptible human cells, is 
molecularly and biologically distinct in the chimpanzee (5). 
HIV-1 envelope proteins allow syncytium formation be- 
tween cells expressing human but not chimpanzee CD4. 
DNA sequence analysis of regions of the CD4 gene which 
govern cell fusion show amino acid heterogeneity between 
the two species; chimpanzee CD4+ cells bearing human 
amino acid residue 87 support syncytium formation, while 
human CD4 cells bearing chimpanzee residue 87 do not. 
Furthermore, infection of human cells expressing the chim- 
panzee CD4 gene is insensitive to lysosomotropic agents, 
implying that viral penetration does not require endocytosis 
as was previously demonstrated with human CD4-express- 
ing cells. The binding affinity of virus to chimpanzee CD4, 
however, remains equivalent to that of human CD4' T cells 
(5, 28). These subtle differences between human and chim- 
panzee CD4 receptors may well be associated with both 
resistance to virus-induced cytopathicity and the character- 
istic low-level virus released from infected lymphocytes (28). 
Perhaps a low level of CD4 expression in an altered config- 
uration plays a role in the resistance of the chimpanzee 
monocyte to virus infection. This could explain the permis- 
siveness of the chimpanzee-passaged HIV-l,Avlb isolate. 
Alternatively, cytokines produced from HIV-1-inoculated 
chimpanzee lymphocytes and monocytes could effect sus- 
ceptibility to HIV-1 infection. Indeed, recent reports dem- 
onstrate that when 2 5  U of alpha interferon per ml is added 
to cultures of human monocytes, HIV-1 infection is abro- 
gated. This block in HIV-1 infection is localized at the level 
of proviral DNA (19, 20). 
Macrophages play essential roles in the virus-specific 
immune response in the host by presenting Ag to lympho- 
cytes during infection and by serving as accessory cells to 
lymphocytes (32). Further indirect evidence of the in vivo 
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FIG. 7. Comparative electron micrographs of HIV-1-infected 
chimpanzee and human PHAIIL-Zstimulated PBMCs. Human and 
chimpanzee PBMCs previously cultured for 3 days in medium with 
PHA and IL-2 were exposed to HIV-1 ADA at a MOI of 0.01. (A and 
B) Focal budding of HIV-1 particles from the surface of a chimpan- 
zee lymphocyte. Note the thickened celVvirus-associated mem- 
branes involved in virus budding in panel B. (C) Cytolytic response 
of human PBMCs to HIV-1. Note the large numbers of virus 
particles associated with cellular debris. Magnification, ~96,000. 
resistance of these cells in chimpanzees comes on the 
realization that after experimental inoculation of large 
amounts of virus or virus-producing cells into animals, a full 
range of virus-specific immunity develops (7) without detect- 
able infection in macrophages (27, 28). This immunity re- 
quires efficient Ag processing of the virus-infected cells in 
mononuclear phagocytes, leading to an abortive infection, 
and thus further supports the findings presented here. Mac- 
rophages also have protective functions through their abili- 
ties to ingest and kill invading microorganisms and therefore 
provide an important element for host defense against dis- 
ease (32). Paradoxically these same cells are targets for a 
number of microbial pathogens including HIV-1. It is of 
particular interest that the target tissues in which large 
numbers of HIV-1-infected macrophages reside constitute 
the identical tissues involved in disease (31). In humans, the 
lung, brain, and spinal cord are all primary sites of replica- 
tion for HIV-1 in the macrophage and all demonstrate 
significant and persistent levels of viral replication which 
correlate with histopathological alterations and clinical dis- 
ease (24). HIV-1-related interstitial pneumonitis, subacute 
encephalopathy, and spinal cord myelopathy are features 
associated with HIV-1 infection of macrophages (24). Fur- 
thermore, the numbers of infected cells correlate with the 
observed histopathology in many cases. Not all tissue mac- 
rophages are equally permissive for lentiviral infections. For 
example, in horses infected with equine infectious anemia 
virus, Kupffer cells present in the liver have been demon- 
strated to be a major site of virus replication (33). In 
HIV-1-infected humans we studied, liver or Kupffer cell 
infection and associated pathology is less frequent (26, 34). 
In a 8-month-old chimpanzee chronically infected with 
HIV-1 IIIB, liver infection was not demonstrated (27). We 
previously demonstrated that monocytes cultured from pe- 
ripheral blood of HIV-l IIB-infected chimpanzees did not 
contain HIV-specific gene products or release progeny viri- 
ons (27, 28). The lack of susceptibility of liver, connective 
tissue, bone, and kidney tissues to pathological processes 
may be traced to the lack of permissiveness of their respec- 
tive tissue macrophages in supporting productive HIV-1 
infection. 
The lack of apparent HIV-1 infection in chimpanzee 
monocytes coupled with the previously reported continuous 
but noncytopathic infection of lymphocytes demonstrate 
two aspects of controlled virus replication in the host and 
further defines the animal models' application to AIDS 
research. Further investigations into the unique aspects of 
these virus-host cell interactions should further elucidate the 
necessary mechanisms that correlate with and precipitate 
disease in humans. This will likely require the use of an 
HIV-1 isolate or strain which efficiently infects chimpanzee 
macrophages in vivo. Indeed, one such virus strain was 
found. Ultimately, understanding the mechanisms of virus 
adaptation to its natural host cells should provide insights 
into the pathogenesis of HIV-1 in its human host. 
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